Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | MRD: decision making in CLL

Susan O’Brien • 1 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Venetoclax

MRD offers a huge advantage in the development of prognostics in chronic lymphocytic leukemia (CLL), but how does the technique impact decision making in the clinical environment? Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses this at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Susan O’Brien

Venetoclax and obinutuzumab combination therapy for CLL 2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
CAR T-cell therapy updates in CLL 2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
CLL RESONATE-2: Five-year follow-up 2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib? 3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101 1:45
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101
Marc Hoffman • 7 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib 3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals